Sanara MedTech Inc.

NASDAQ:SMTI

Medical - Instruments & Supplies

Healthcare
$32.73 +3.44%

+$0.73 today

Market cap
$300.55M
Beta
1.19
P/E (TTM)
-5.7
EPS (TTM)
-$3.86
52W Low $16.05High $35.95

Volume 0.07M

Average 0.06M

SMTI Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Sanara MedTech Inc.NASDAQ: SMTI

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $759.59K fell 31.8% year over year, behind the -13.4% change in trailing-twelve-month research & development. Sequentially, it fell 62.7% from the prior quarter. Over 3 fiscal years it compounded at +14.6% a year.

Context

  • Research & development amounted to 4.9% of revenue in FY2025, down 1.7 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -31.8% toward the trailing-twelve-month pace of -13.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$759.59K-62.7% QoQ
Last fiscal yearDec 2025
$5.07M-11.1% YoY
LTMMar 2026
$5.08M-13.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-31.8%——
1 year-11.1%——
3-year CAGR+14.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
5.07M USD
Year-over-year change
-11.1%
4-year CAGR
+73.6%

Research & Development vs competitors

How SMTI compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -13.4% is the 7th highest of 9, against a peer median of +2.5%.
  • Research & development amounts to 4.7% of revenue for SMTI, versus a peer median of 9.5%.
SMTI Competitors
Research & Development for SMTI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$143.25M USD+11.2%+28.8%2496.5%
TBRGTruBridge, Inc.LTM Mar 2026$39.88M USD+24.6%+1.7%11.5%
NEONeoGenomics, Inc.LTM Jun 2026$38.17M USD+9.5%+6.9%5.0%
SGHTSight Sciences, Inc.LTM Mar 2026$12.72M USD-28.5%-13.9%16.0%
STXSStereotaxis, Inc.LTM Mar 2026$9.43M USD-4.4%-3.9%30.2%
LFMDLifeMD, Inc.LTM Mar 2026$7.53M USD-25.4%+35.2%3.4%
XGNExagen Inc.LTM Mar 2026$6.52M USD+16.5%-14.1%9.5%
SMTISanara MedTech Inc.LTM Mar 2026$5.08M USD-13.4%+14.6%4.7%
VMDViemed Healthcare, Inc.LTM Mar 2026$2.8M USD-10.1%+3.8%1.0%
HITIHigh Tide Inc.LTM Apr 2026CA$0 CAD——0.0%
Peer median (excluding SMTI) —+2.5%+2.8%9.5%

Competitors are the stored peer set for SMTI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue24.14M45.84M64.99M86.67M103.12M
Cost of Revenue2.31M6.36M7.85M8.14M10.18M
Gross Profit21.83M39.48M57.14M78.53M92.94M
Gross Margin90.4%86.1%87.9%90.6%90.1%
Research & Development558.7K3.37M4.13M5.7M5.07M
Selling, General & Admin28.05M45.98M56.99M76.56M78.72M
Operating Expenses29.21M52M61.35M85.25M83.79M
Depreciation & Amortization771.93K2.37M3.68M4.92M2.66M
EBITDA(7.22M)(11.57M)(289.1K)(1.86M)9.03M
EBITDA Margin-29.9%-25.2%-0.4%-2.1%8.8%
Operating Income(7.38M)(12.52M)(4.22M)(6.72M)9.15M
Operating Margin-30.6%-27.3%-6.5%-7.7%8.9%
Interest Income0284.75K021.98K3.67K
Interest Expense711284.75K475.78K3.13M6.76M
Other Income / Expenses(617.64K)(1.42M)(224.75K)(3.2M)(9.54M)
Income Before Tax(7.99M)(13.94M)(4.44M)(9.91M)(393.12K)
Pre-Tax Margin-33.1%-30.4%-6.8%-11.4%-0.4%
Income Tax Expense0(5.84M)000
Net Income(7.92M)(7.94M)(4.3M)(9.66M)(37.56M)
Net Margin-32.8%-17.3%-6.6%-11.2%-36.4%
EPS (Basic)(1.08)(1.00)(0.52)(1.14)(4.36)
EPS (Diluted)(1.08)(1.00)(0.52)(1.14)(4.36)
Weighted Avg Shares7.34M7.91M8.28M8.48M8.62M
Weighted Avg Shares (Diluted)7.34M7.91M8.28M8.48M8.62M

Sanara MedTech Inc.

NASDAQ:SMTI

Intrinsic Alpha fair value

Locked

Current Price

$32.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.